Figures & data
Figure 1 Schematic and structural illustration of the synthetic pathway in preparation of PVCL-DOX nano-hydrogel.
Abbreviations: PVCL, poly(N-vinylcaprolactam); DOX, doxorubicin.
![Figure 1 Schematic and structural illustration of the synthetic pathway in preparation of PVCL-DOX nano-hydrogel.Abbreviations: PVCL, poly(N-vinylcaprolactam); DOX, doxorubicin.](/cms/asset/2c8568f5-5ff2-4ed8-a76d-c8eb56c60be0/dijn_a_214467_f0001_c.jpg)
Figure 2 1HNMR spectra of PVCL-PEG and PVCL-Lys.
Abbreviations: PVCL, poly(N-vinylcaprolactam); PEWG, poly(ethylene glycol).
![Figure 2 1HNMR spectra of PVCL-PEG and PVCL-Lys.Abbreviations: PVCL, poly(N-vinylcaprolactam); PEWG, poly(ethylene glycol).](/cms/asset/10a919c1-2c97-4fd3-9f59-39f6efd77a3a/dijn_a_214467_f0002_c.jpg)
Figure 3 TEM image of PVCL-Lys at (A) room temperature (<LCST) and (B) at 42°C (>LCST).
Abbreviations: TEM, transmission electro microscopy; PVCL, poly(N-vinylcaprolactam); LCST, lower critical solution temperature.
![Figure 3 TEM image of PVCL-Lys at (A) room temperature (<LCST) and (B) at 42°C (>LCST).Abbreviations: TEM, transmission electro microscopy; PVCL, poly(N-vinylcaprolactam); LCST, lower critical solution temperature.](/cms/asset/98591e63-f846-4d69-9db2-eb5b99169253/dijn_a_214467_f0003_b.jpg)
Figure 4 Cryo TEM image of PVCL-Lys nano-hydrogel.
Abbreviations: TEM, transmission electro microscopy; PVCL, poly(N-vinylcaprolactam).
![Figure 4 Cryo TEM image of PVCL-Lys nano-hydrogel.Abbreviations: TEM, transmission electro microscopy; PVCL, poly(N-vinylcaprolactam).](/cms/asset/71d79a01-944f-4987-8ead-88f5579aae81/dijn_a_214467_f0004_c.jpg)
Figure 5 Release profile of PVCL-DOX in regard to temperature and pH changes.
Abbreviations: PVCL, poly(N-vinylcaprolactam); DOX, doxorubicin.
![Figure 5 Release profile of PVCL-DOX in regard to temperature and pH changes.Abbreviations: PVCL, poly(N-vinylcaprolactam); DOX, doxorubicin.](/cms/asset/8cad3d35-c96f-4ff9-86fa-5cbfd261d91f/dijn_a_214467_f0005_c.jpg)
Figure 6 MTT Cytotoxic assay regarding different concentrations of free DOX, PVCL-Lys and PVCL-DOX on MCF-7 cell line (*P<0.05). (A and B) Cytotoxicity assessment of free DOX and PVCL-DOX with equal DOX concentration of free DOX in 24 hrs and (B) 48 hrs. (C) Cytotoxicity assessment of PVCL-Lys in 24 and 48 hrs.
Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).
![Figure 6 MTT Cytotoxic assay regarding different concentrations of free DOX, PVCL-Lys and PVCL-DOX on MCF-7 cell line (*P<0.05). (A and B) Cytotoxicity assessment of free DOX and PVCL-DOX with equal DOX concentration of free DOX in 24 hrs and (B) 48 hrs. (C) Cytotoxicity assessment of PVCL-Lys in 24 and 48 hrs.Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).](/cms/asset/a3a811c3-bd8b-4e58-9542-211d9f740c34/dijn_a_214467_f0006_c.jpg)
Figure 7 MCF-7 cellular uptake assessment; images of confocal laser scanning microscopy after 24 and 48 hrs treatment of (A and D) DOX with three different concentrations (I: 1.2 µg/mL, II: 0.6 µg/mL, III:0.3 µg/mL), (B and E) PVCL-DOX and (C and F) PVCL-Rhod with three different concentrations (I: 60 µg/mL, II: 30 µg/mL, III: 15 µg/mL).
Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).
![Figure 7 MCF-7 cellular uptake assessment; images of confocal laser scanning microscopy after 24 and 48 hrs treatment of (A and D) DOX with three different concentrations (I: 1.2 µg/mL, II: 0.6 µg/mL, III:0.3 µg/mL), (B and E) PVCL-DOX and (C and F) PVCL-Rhod with three different concentrations (I: 60 µg/mL, II: 30 µg/mL, III: 15 µg/mL).Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).](/cms/asset/538b8dff-9dc2-45d3-a90e-26b4ea6301d1/dijn_a_214467_f0007_c.jpg)
Figure 8 Histogram plots of flowcytometry analysis of the treated MCF-7 cells with DOX, PVCL-DOX, and PVCL-Rhod 4, 24, and 48 hrs. (A) The gray, green, red, and blue plots belong to the untreated cells, III:0.3, II:0.6, and I:1.2 µg/mL concentrations of DOX, respectively. (B and C) The gray, green, red, and blue plots belong to the untreated cells, III:15, II:30, and I:60 µg/mL concentrations of PVCL-DOX and PVCL-Rhod, respectively.
Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).
![Figure 8 Histogram plots of flowcytometry analysis of the treated MCF-7 cells with DOX, PVCL-DOX, and PVCL-Rhod 4, 24, and 48 hrs. (A) The gray, green, red, and blue plots belong to the untreated cells, III:0.3, II:0.6, and I:1.2 µg/mL concentrations of DOX, respectively. (B and C) The gray, green, red, and blue plots belong to the untreated cells, III:15, II:30, and I:60 µg/mL concentrations of PVCL-DOX and PVCL-Rhod, respectively.Abbreviations: DOX, doxorubicin; PVCL, poly(N-vinylcaprolactam).](/cms/asset/5192be7f-e9ff-426c-b4c7-5bfd0f2a86de/dijn_a_214467_f0008_c.jpg)
Figure S1 FT-IR spectra of PVCL-PEG and PVCL-Lys.
Abbreviations: PVCL, poly(N-vinylcaprolactam); PEWG, poly(ethylene glycol).
![Figure S1 FT-IR spectra of PVCL-PEG and PVCL-Lys.Abbreviations: PVCL, poly(N-vinylcaprolactam); PEWG, poly(ethylene glycol).](/cms/asset/b2d7f361-7d6b-4f08-8be3-9064cea25fb7/dijn_a_214467_sf0001.jpg)